BCL2 and lymphoma: Parallel mechanisms involve mitochondrial regulation of apoptosis—overexpression of anti-apoptotic BCL-2 proteins (e.g., in lymphomas and breast cancers) blocks cytochrome c-mediated apoptosome activation, a vulnerability successfully targeted by the BCL-2 inhibitor venetoclax (63).